Ashish Misra, Peter J. Psaltis, Amandeep Rashid Mondal, Adam J. Nelson, Stefan Mark Nidorf
{"title":"Implications and limitations of the CLEAR-SYNERGY trial for the use of low-dose colchicine in cardiovascular disease","authors":"Ashish Misra, Peter J. Psaltis, Amandeep Rashid Mondal, Adam J. Nelson, Stefan Mark Nidorf","doi":"10.1038/s44161-024-00600-2","DOIUrl":null,"url":null,"abstract":"Low-dose colchicine is the only anti-inflammatory drug approved for secondary prevention of coronary disease. The CLEAR-SYNGERY trial of colchicine in acute myocardial infarction challenges the results of previous colchicine trials; however, clinicians should be aware of how its design and the COVID-19 pandemic affected the trial outcome.","PeriodicalId":74245,"journal":{"name":"Nature cardiovascular research","volume":"4 3","pages":"251-253"},"PeriodicalIF":10.8000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cardiovascular research","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44161-024-00600-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Low-dose colchicine is the only anti-inflammatory drug approved for secondary prevention of coronary disease. The CLEAR-SYNGERY trial of colchicine in acute myocardial infarction challenges the results of previous colchicine trials; however, clinicians should be aware of how its design and the COVID-19 pandemic affected the trial outcome.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
